Clorox: The "Half-Off" Fair-Value Call Rests on One Number

Clorox: The "Half-Off" Fair-Value Call Rests on One Number

The market is quoting two versions of The Clorox Company, and both are defensible. On the sell side, CLX trades at $106.69 (as of Aug. 22), a $12.9 billion staples giant paying a ~4.7% dividend after more than two decades of consecutive annual increases — and the average analyst price target clusters right around the quote, at roughly $100 to $106, with the last year's stream of revisions almost entirely downward. In the model shops, the same company screens as dramatically undervalued: fair-value estimates published over the past year run from about $105 to $163, and the most aggressive calls frame the shares as roughly half off their intrinsic worth.

Both camps are looking at the same facts. They are fighting over what those facts are worth, and the fight collapses into one number — gross margin. The bulls need it to revert toward the mid-40s. The bears point out that management's own plan is built on 42%. That gap, not the dividend or the multiple, is the whole duel.

Shared facts card

As-of Aug. 22, 2026; price $106.69; market cap $12.9 billion; enterprise value $17.8 billion; net debt ~$4.9 billion against $7.5 billion of total debt. Fifty-two-week range $84.70–$128.90; the stock is down ~16% over five months but up ~12% over the last month, after a bruising stretch that took it deep into the $80s.

Fiscal 2026 (year ended June 2026): net sales $6.72 billion, down 5%; adjusted EPS $5.53, down 28% from $7.72; GAAP EPS $4.81, down 26%; gross margin 42.3%, off 290 basis points from 45.2%. Fourth quarter: adjusted EPS $1.66 (a couple of cents above consensus), reported sales $1.95 billion down 2% — with the GOJO acquisition adding about 10 points, organic sales fell 13%. Operating cash flow came in at $612 million, down 38% year over year.

Fiscal 2027 guidance: net sales up 13% to 14% to $7.6–$7.7 billion (above the ~$7.5 billion consensus, with ~9.5 points from GOJO); adjusted EPS of $5.70–$6.00, below the $6.23 consensus; gross margin held at roughly 42%.

On valuation, agreed by both: trailing P/E near 22x, about 18x the midpoint of fiscal 2027 adjusted-EPS guidance, and ~15.4x trailing EV/EBITDA — versus roughly 21x for Colgate-Palmolive and Church & Dwight and ~15.7x for Procter & Gamble. Clorox is the cheapest of the group by a wide stretch.

Round 1: The bull — three one-time excuses, all winding down

The bull's opening move is to list what hit fiscal 2026 and then check each item off as transient. The August 2023 cyberattack wrecked 2024. The U.S. ERP implementation — the enterprise-resource-planning software overhaul that took five years and about $580 million — distorted 2025 and 2026 from either side. And the GOJO/Purell acquisition closed in April 2026 with its inventory step-up and integration costs landing inside the year.

The ERP point is the bull's legitimately clever one, because it cuts both ways and they use it straight. Retailers stocked up ahead of the system switch in fiscal 2025, gifting that year roughly 3.5 points of sales and about $0.90 of EPS; in fiscal 2026 they drew that inventory down, charging the same ~7.5 points and ~$0.90. Fiscal 2027 laps the whole thing, adding back more than 3.5 points of organic growth before anyone sells an extra bottle of bleach. Underneath the optics, the brands were not dying: International grew organically, and health-and-wellness categories ex-ERP were climbing.

Then there is GOJO. Clorox paid $2.25 billion in cash — about $1.92 billion net of expected tax benefits — for the maker of Purell, a leader in skin health and hygiene, closing in April 2026. The deal adds ~9.5 points to fiscal 2027 sales and tilts the mix toward the higher-margin, professional-channel health-and-hygiene business, which now represents more than half of that portfolio. The bull reads this as a portfolio upgrade, not a gamble.

The payout question: normalize gross margin back to the mid-40s as ERP comparisons, the Purell step-up, and integration costs wash out, and normalized EPS lands near $6.50 to $7. Morningstar's $163 fair value is built on exactly that — 16x EV/adjusted EBITDA on depressed fiscal 2026 numbers, high-teens operating margins, roughly 4% long-run sales growth, and mid-40s gross margins over time. Screen-based fair values of $134–$145 appeared as early as late 2025 on the same normalization logic. A dividend grower with two decades-plus of raises at a decade-low multiple with a near-record 4.7% yield and reported returns on invested capital that even the conservative market-data screens put at ~17% — the bull says the market is pricing a broken compounder as if the franchise were gone.

Bull's best punch: even the most generous skeptical model — Morningstar, which is hardly a momentum house — publishes $163, or about 53% above the current price. You have to strain to find a credible screen that says Clorox is fairly priced at $106. The bull wins this round on the direction of the mispricing.

Round 2: The bear — the guidance is the tell

The bear's opening move is to point at the company's own fiscal 2027 plan, which is the single most bearish document in circulation. Management guided adjusted EPS to $5.70–$6.00 — below the $6.23 the sell side expected — and held gross margin at ~42%, describing the year as inflationary headwinds and negative mix roughly offsetting cost savings. A company that believed its margin trough was cyclical doesn't usually guide flat margin the year after the trough. The plateau is the forecast.

Strip the ERP lap out of the organic-sales guide. The company calls for 3.5% to 4.5% organic growth, but more than 3.5 points of that is the inventory-rebuild rebound. The underlying number is roughly zero to one percent organic growth — respectable for a bank, modest for a housewares staple, and nowhere near the platform-growth story the bull's multiple assumes.

The demand side of the bear case is the uncomfortable one. This is not a pure accounting story: fourth-quarter organic sales fell 13% reported, with Household down 18% and Health & Wellness down 12%, in a consumer environment where shoppers are visibly trading down to private label in exactly the categories — trash bags, cat litter, coffee — where Clorox's premium pricing is hardest to defend. Tariffs and commodity costs have not cooperated either. That is why the discount to fast-growing peers is earned: 15x EV/EBITDA versus Colgate's 21x looks like a bargain only if Clorox were growing like Colgate. It is growing backward.

And the balance sheet. The GOJO deal was largely debt-funded: net debt of ~$4.9 billion is roughly 4x trailing EBITDA, S&P downgraded Clorox to BBB from BBB+ in February, buybacks have gone quiet, and trailing free cash flow of ~$405 million covers only about two-thirds of the ~$600 million annual dividend. The dividend is being defended, yes — it was raised a token quarter this year to $1.25 — but at an 80–90% payout of adjusted earnings, it is leaning on the 42% margin holding and Purell cash flow arriving on schedule.

This is why the Street now looks like a choir of the underwhelmed: Barclays $84 and sell, JPMorgan $95 and sell, Goldman's target cut to the $83–94 zone over the year, Jefferies flipped from Buy to Hold at $98, UBS and Wells Fargo holding in the $102–105 area, and RBC the outlier at $110. The average target sits where the stock trades. The bear wins this round on the weight of evidence: the "recovery" is real but small, and guidance is the only document the company has to answer for.

Round 3: What the "half-off" price actually requires

Reverse the price before choosing a side. For Clorox to be 50%-plus below fair value, fair value would have to be roughly $210–$240. That requires normalized EPS of $8 or more — gross margin all the way back to 45%–46%, organic growth re-accelerating, Purell synergies delivered in full, and interest cost not rising — capitalized at 25x-plus earnings. That is not a recovery; that is a growth-stock re-rating on top of a growth-stock earnings outcome.

The credible screen spectrum is much narrower. A DCF-style model at the top of the public search sits right at the price (~$105). GF Value-type math puts the number near $135. The value-investing screens run $134–$145. Morningstar's $163 is the ceiling of the responsible range — and even that figure, the most generous credible estimate on the board, implies the stock is roughly 35% below fair value, not half. The difference between "a third below fair value" and "half below fair value" is the entire argument, and it is carried entirely by the gross-margin assumption.

Now convert the price into an operating path. At ~18x the midpoint of guided fiscal 2027 earnings and a ~4.7% yield, the market is not pricing distress. It is pricing exactly the modest recovery the company guided to — EPS up 3% to 8%, organic barely positive ex-lap — and refusing to award any multiple expansion for it. The dividend pays you to wait, which is the honest compensation for a stock whose near-term growth is a rounding error. The bull's $130–$163 range only works if the 42% gross-margin plateau turns out to be a trough; the bear's $84–$95 range only works if that plateau cracks and organic growth stays negative. Both camps agree the swing variable is one number.

Verdict

Bull on the business, bear on the claim. The Clorox franchise — dominant category brands, a moat rating even its skeptics concede, returns on capital above its cost of capital on any reasonable definition, and a dividend streak income investors prize — is not a value trap. But "roughly half off fair value" is a one-number bet management has declined to underwrite, and at this price the burden of proof sits with whoever pays a growth multiple for the recovery in advance. The honest range is "modestly undervalued to roughly fair," topping out around a third below fair value on the most generous credible screen. That makes CLX an income stock with a genuine margin-recovery catalyst and favorable downside asymmetry — not a mispriced bargain waiting to snap back. On the question the market actually cares about — is this a 50% mispricing or a fairly priced defensive compounder? — the bears win on size, and the bulls win on patience: neither extreme is well-armed, but the low multiple and the yield make the waiting profitable.

The stock call, in one line: hold the compounder, buy the margin. The ruling flips when gross margin moves.

The reversal clause

The tripwire is fiscal Q1 2027, reported around late October or early November 2026 — the first clean quarter: a full three months of Purell in the numbers and no ERP comparison noise. Confirmed gross margin above ~43% with organic sales ex-lap of at least ~1% validates the floor, and the bull's $130–$163 working range takes over. Gross margin slipping under ~41%, or organic ex-lap negative while leverage stays near 4x EBITDA, hands the debate to the bear's $84–$95 zone — and returns the dividend-coverage question to the top of the list. The earlier tone check is the Barclays Global Consumer Staples Conference on Sept. 9, where the C-suite is scheduled to talk publicly for the first time since the guidance.